Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

Next Previous
X
Search
Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Corticosteroids; Methotrexate; Prednisone
  • Indications Giant cell arteritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GiACTA
  • Sponsors Genentech; Roche

    • Most Recent Events

    • 16 Nov 2022 Results evaluating longitudinal effects of both glucocorticoids (GCs) and tocilizumab, on hemoglobin A1c (HbA1c) during GC tapering, published in the Arthritis and Rheumatology
    • 14 Nov 2022 Results of post-hoc analysis assessing glucocorticoid toxicity in the treatment of giant cell arteritis, presented at the ACR Convergence 2022.
    • 01 Dec 2021 Results published in the American Journal of Respiratory and Critical Care Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top